Elekta AB (OTCMKTS:EKTAY) Short Interest Down 45.6% in August

Elekta AB (OTCMKTS:EKTAY) saw a large decrease in short interest in August. As of August 31st, there was short interest totaling 3,337 shares, a decrease of 45.6% from the August 15th total of 6,134 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 6,268 shares, the days-to-cover ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.

Elekta Price Performance

Shares of Elekta stock remained flat at $5.29 during mid-day trading on Wednesday. 1,541 shares of the stock traded hands, compared to its average volume of 1,905. The firm’s 50-day simple moving average is $5.26 and its 200-day simple moving average is $5.63. Elekta has a twelve month low of $4.35 and a twelve month high of $6.93. The company has a current ratio of 0.87, a quick ratio of 0.68 and a debt-to-equity ratio of 0.47. The company has a market cap of $1.95 billion, a price-to-earnings ratio of -44.04 and a beta of 1.05.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings results on Thursday, August 27th. The company reported $0.07 earnings per share (EPS) for the quarter. Elekta had a negative net margin of 2.38% and a positive return on equity of 13.31%. The business had revenue of $372.30 million during the quarter. Sell-side analysts expect that Elekta will post 0.43 earnings per share for the current year.

About Elekta

Elekta AB is a Sweden-based medical technology company focused on radiation oncology and precision treatment solutions. The company develops and supplies systems used to diagnose, plan and deliver treatments for cancer and other conditions affecting the brain and nervous system.

Its product portfolio includes linear accelerators for external-beam radiotherapy, stereotactic radiosurgery systems such as Leksell Gamma Knife, brachytherapy equipment and treatment-planning, oncology information and workflow software.